Shares of Pain Therapeutics (NASDAQ:PTIE) were down 3% during mid-day trading on Tuesday . The company traded as low as $2.57 and last traded at $2.57, with a volume of 93,419 shares changing hands. The stock had previously closed at $2.65.

Separately, Zacks Investment Research upgraded Pain Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 31st.

The firm’s market capitalization is $119.97 million. The stock’s 50 day moving average price is $2.44 and its 200 day moving average price is $2.21.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. Analysts forecast that Pain Therapeutics will post ($0.42) earnings per share for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.